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Abstract
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 (PD-L1) monotherapies have shown prom-
ising clinical activity in advanced, refractory nonesmall-cell lung cancer (NSCLC), but antitumor activity appears to be
greater in patients with PD-L1þ tumors compared with patients harboring PD-L1 tumors. Combining the anti-PD-L1
antibody durvalumab and the anti-cytotoxic T-lymphocyte antigen 4 antibody tremelimumab offers the potential for
antitumor activity in patients with advanced NSCLC, regardless of PD-L1 tumor status. ARCTIC (NCT02352948) is a
global, phase III, randomized, open-label multicenter study in patients with advanced NSCLC assessing the safety and
clinical activity of durvalumab versus standard of care (SoC; erlotinib, gemcitabine, or vinorelbine) in patients with PD-
L1þ tumors (25% of tumor cells with membrane staining using VENTANA PD-L1 [SP263] CDx Assay) (Sub-study A)
and the combination of durvalumab þ tremelimumab or either agent as monotherapy versus SoC in patients with PD-
L1 tumors (Sub-study B). Eligible patients are those with locally advanced or metastatic NSCLC (Stage IIIB/IV),
without epidermal growth factor receptor tyrosine kinase activating mutations or anaplastic lymphoma kinase rear-
rangements, who have received at least 2 prior systemic regimens, including 1 platinum-based chemotherapy
regimen. Co-primary endpoints are progression-free survival and overall survival. Secondary endpoints include the
proportion of patients alive at 12 months, objective response rate, duration of response, progression-free survival at 6
and 12 months, safety and tolerability, pharmacokinetics, immunogenicity, and quality of life. The exploratory end-
points will assess potential biomarkers of treatment response. Recruitment started in January 2015 and is ongoing.
Clinical Lung Cancer, Vol. 17, No. 3, 232-6 ª 2016 Elsevier Inc. All rights reserved.
Keywords: Anti-CTLA-4, Anti-PD-L1, ALK, EGFR, Tumor membrane stainingIntroduction clinical need for improvements in treatment.1 Programmed cell
Current therapies for advanced refractory nonesmall-cell lung
cancer (NSCLC) are associated with poor outcomes, highlighting a1Department of Medical Oncology, Gustave Roussy, Villejuif, France
2First Department of Internal Medicine, Kansai Medical University, Osaka, Japan
3Florida Cancer Specialists and Research Institute, Fort Myers, FL
4Department of Internal Medicine II, Lungenklinik Löwenstein GmbH, Löwenstein,
Germany
5Department of Internal Medicine, Chonnam National University Medical School,
Hwasun Hospital, Hwasun, Jeonnam, South Korea
6Global Medical Development (GMD), AstraZeneca, Gaithersburg, MD
7Biometrics and Information Sciences, AstraZeneca, Gaithersburg, MD
8DITEP (Département d’Innovations Thérapeutiques et Essais Précoces), Gustave
Roussy, Villejuif, France
Submitted: Mar 1, 2016; Accepted: Mar 8, 2016; Epub: Mar 17, 2016
Address for correspondence: David Planchard, MD, PhD, Gustave-Roussy, Department
of Medical Oncology, Thoracic Unit, 114 Rue Edouard Vaillant, 94805 Villejuif, France
E-mail contact: David.PLANCHARD@gustaveroussy.fr
Clinical Lung Cancer May 2016death-1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4)
are 2 main immune checkpoints activated by tumors to suppress
antitumor T-cell responses. Targeted antibody blockade of these
immunosuppressive pathways to restore antitumor T-cell activity is
a promising new treatment strategy.2 Anti-PD-1 or anti-
programmed cell death ligand-1 (PD-L1) agents block suppression
of T-cell function via inhibitory receptors and mainly function
within the tumor microenvironment. By contrast, anti-CTLA-4
agents act primarily in lymphoid organs to expand the numbers
and repertoire of tumor-reactive T cells.3,4 Single-agent antibodies
against PD-1 or PD-L1 have demonstrated antitumor activity in
clinical trials of patients with advanced NSCLC.2,5-8
The anti-PD-1 agents, nivolumab and pembrolizumab, recently
received United States Food and Drug Administration approval for
use in previously treated, metastatic NSCLC. Pembrolizumab is1525-7304/$ - see frontmatter ª 2016 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cllc.2016.03.003
approved only in patients with PD-L1þ NSCLC.2,9 The majority of
evidence for both agents suggests that clinical activity is limited for
the subset of patients with PD-L1 (squamous or non-squamous)
NSCLC,2,5,7,10 and most of this population would not be ex-
pected to derive signiﬁcant beneﬁt from anti-PD-1/PD-L1 mono-
therapy over current standard of care (SoC). A nivolumab study in
272 patients with squamous NSCLC showed similar response rates
for patients with PD-L1þ and PD-L1 tumors.8
Durvalumab (MEDI4736) is a selective, high-afﬁnity, engineered
human IgG1 monoclonal antibody (See Supplemental Figure 1A in
the online version) that blocks PD-L1 binding to PD-1 (IC50 0.1
nM) and CD80 (IC50 0.04 nM).
6,11 Durvalumab does not bind to
programmed cell death ligand-2,11 which plays a role in controlling
inﬂammation in normal lung tissue. This may help avoid potential
immune-related toxicity due to programmed cell death ligand-2
blockade, noted from animal data.6 An engineered triple mutation
in the Fc antibody domain is designed to reduce antibody-
dependent cell-mediated cytotoxicity and complement-dependent
cytotoxicity.11 In an ongoing phase I/II study of durvalumab
monotherapy (NCT01693562), encouraging durable antitumor
activity was observed in patients with advanced NSCLC, together
with a manageable tolerability proﬁle (Grade 3/4 drug-related
adverse events [AEs] in 8% of patients, drug-related AEs leading
to discontinuation in 5%). Conﬁrmed objective response rates
(ORRs) with durvalumab 10 mg/kg every 2 weeks (q2w) (range of
ongoing responses, 0.1þ to 54.4þ weeks) were higher in patients
with PD-L1þ tumors (27%; 95% conﬁdence interval [CI], 18.2-
38.2) versus PD-L1 tumors (<25% tumor cells stained; 5%; 95%
CI, 1.8-12.2).6 Similarly, differential ORRs in patients with PD-
L1þ (22%) versus PD-L1 (8%) NSCLC were reported for the
anti-PD-L1 agent, atezolizumab.12
Tremelimumab is a selective human IgG2 monoclonal antibody
inhibitor of CTLA-4 that promotes T-cell activity but does not
deplete regulatory T cells13 (See Supplemental Figure 1B in the
online version). In preclinical studies, anti-PD-L1 and anti-CTLA-4
antibody combinations have demonstrated enhanced antitumor
activity compared with either agent alone, indicating that the 2
pathways are non-redundant.14 Similar results have been observed
by combining PD-1 and CTLA-4 inhibitors in a clinical study of
untreated melanoma.15 On the basis of these data, targeting both
PD-1/PD-L1 and CTLA-4 pathways has the potential for additive
or synergistic effects on antitumor responses.
A study combining nivolumab with the CTLA-4 inhibitor ipi-
limumab in NSCLC showed durable responses in patients with
PD-L1 as well as PD-L1þ tumors. However, initial doses of the
combination were associated with tolerability issues (Grade 3/4
drug-related AEs in 48% of patients).16 The phase I CheckMate
012 trial showed better tolerability after dose level adaptation
(Grade 3/4 drug-related AEs in 28%-35% of patients) with
conﬁrmed ORR (13%-39%) and encouraging median progression-
free survival (PFS; range, 4.9-10.6 months).17 A phase Ib study
combining durvalumab with tremelimumab in patients with
advanced NSCLC (NCT02000947) also demonstrated antitumor
activity regardless of PD-L1 status, including in patients with no
tumor cell membrane PD-L1 staining. In the combined durvalumab
10 to 20 mg/kg every 4 weeks (q4w) or q2w þ tremelimumab 1
mg/kg patient cohort, 30% of patients had Grade 3/4 drug-relatedAEs, and 16% discontinued treatment owing to drug-related AEs.
Conﬁrmed ORR was 6 of 26 (23%; 95% CI, 9-44): 2 of 9 (22%;
95% CI, 3-60) in patients with PD-L1þ tumors and 4 of 14 (29%;
95% CI, 8-58) in patients with PD-L1e tumors (<25% staining).
In the subset of patients with PD-L1e tumors who had 0% stain-
ing, conﬁrmed ORR was 4 of 10 (40%; 95% CI, 12-74). From
these data, the durvalumab 20 mg/kg þ tremelimumab 1 mg/kg
dose was selected for phase III studies.14
The phase III ARCTIC study (NCT02352948) will investigate
the safety and clinical activity of durvalumab monotherapy versus
SoC in patients with PD-L1þ NSCLC and durvalumab combined
with tremelimumab or either agent as monotherapy versus SoC in
patients with PD-L1 NSCLC.
Materials and Methods
Study Design and Dosing Regimen
This is a global, randomized, open-label, multicenter study in
adult patients with locally advanced or metastatic NSCLC (Stage
IIIB/IV), without epidermal growth factor receptor tyrosine kinase
activating mutations or anaplastic lymphoma kinase rearrangements,
who have received at least 2 prior systemic regimens, including 1
platinum-based chemotherapy regimen.
The umbrella study design includes 2 sub-studies (Figure 1). In Sub-
study A, patients with PD-L1þ tumors (25% tumor cells stained
using the PD-L1 [SP263] assay; Ventana Medical Systems, Tucson,
AZ) will be randomized 1:1 to durvalumab (10 mg/kg intravenously
(i.v.) q2w for up to 12 months) or 1 of 3 SoC regimens: erlotinib (150
mg once a day by oral administration); gemcitabine (1000 mg/m2 i.v.
over 30minutes onDays 1, 8, and 15 of a 28-day cycle); or vinorelbine
(30mg/m2 i.v. onDays 1, 8, 15, and 22 of a 28-day cycle) for as long as
patients derive clinical beneﬁt. In Sub-study B, patients with PD-L1
tumors will be randomized 3:2:2:1 to receive either durvalumab and
tremelimumab (durvalumab 20 mg/kg i.v. q4w þ tremelimumab 1
mg/kg i.v. q4w for up to 12weeks then durvalumab alone 10mg/kg i.v.
q2w for 34 weeks), SoC (as in Sub-study A), durvalumabmonotherapy
(as in Sub-study A) or tremelimumabmonotherapy (10mg/kg i.v. q4w
for 24 weeks then q12w for 24 weeks).
Following Independent Ethics Committee/Institutional Review
Board approval of the study protocol, patients will be enrolled from
approximately 250 sites in countries from North America, Latin
America, Asia, Europe, and Australia (randomization targets of 250
and 480 patients for Sub-studies A and B, respectively).
Eligibility Criteria
Main patient inclusion and exclusion criteria are detailed in
Table 1.
Co-Primary Study Endpoints
For both sub-studies, efﬁcacy versus SoC will be determined
using co-primary endpoints of overall survival (OS) and PFS
assessed by Blinded Independent Central Review according to
Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 for
up to 3 years after the start of the study.
Statistical Considerations
Co-primary endpoints will be evaluated in the intent-to-treat
population, testing hypotheses of improved PFS and OS in theClinical Lung Cancer May 2016 - 233
Figure 1 Study Design
Abbreviations: PD ¼ Progressive disease; PD-L1 ¼ programmed cell death ligand-1; RECIST ¼ Response Evaluation Criteria In Solid Tumors; SoC ¼ standard of care. aPD-L1 status assessed via the
Ventana PD-L1 immunohistochemistry (SP263) assay using a recent image-guided core needle (at least 18 gauge) biopsy or archived formalin-ﬁxed parafﬁn-embedded tissue. Baseline study
assessments made during screening. Disease assessment (RECIST v1.1) at screening and every 8 weeks, thereafter. bPatients in the monotherapy arms who demonstrate disease control through to
the end of the 12-month treatment period will be offered re-treatment upon evidence of PD. Patients in the durvalumab þ tremelimumab arm who achieve and maintain disease control through to the
end of Cycle 4 (Week 16; 4 weeks after the last dose of combination treatment) may restart combination treatment upon evidence of PD, with or without conﬁrmation, during the durvalumab
monotherapy part of the combination schedule.
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tively. Stratiﬁed log-rank tests will be used to adjust for type of SoC
therapy and histology.
Secondary Study Endpoints
The following efﬁcacy endpoints will be assessed for durvalumab
versus SoC in Sub-study A and for durvalumab and tremelimumab
versus SoC in Sub-study B: the proportion of patients alive at 12
months from randomization; ORR; the duration of response; the
proportion of patients alive and progression-free at 6 months from
randomization (assessed by Blinded Independent Central Review
according to RECIST v1.1); and the time from randomization to
second progression (as deﬁned by local standard clinical practice). In
Sub-study B, PFS and OS will be compared for the durvalumab þ
tremelimumab combination arm versus the durvalumab mono-
therapy and tremelimumab monotherapy arms and also for the
durvalumab and tremelimumab monotherapy arms versus SoC.
Safety and tolerability endpoints will include assessment of AEs,
physical examinations, vital signs, and laboratory ﬁndings. An in-
dependent data monitoring committee will meet regularly to reviewClinical Lung Cancer May 2016safety assessments. Other endpoints will assess quality of life;
pharmacokinetic proﬁles of durvalumab and tremelimumab; and
immunogenicity (monitoring of anti-drug antibody and neutralizing
anti-drug antibody levels).
Exploratory Study Endpoints (Both Sub-Studies)
These will include an analysis of peripheral and tumoral bio-
markers and an evaluation of potential biomarkers associated
with disease progression and/or identifying patients likely to
respond to treatment (See Supplemental Table 1 in the online
version).
Study Assessments
For objective tumor assessment, computed tomography/mag-
netic resonance imaging scans of the chest and abdomen will be
reviewed by 2 independent radiologists for Blinded Independent
Central Review using RECIST v1.1 and adjudicated, if required.
These will be conducted at screening and every 8 weeks for the
ﬁrst 48 weeks of the treatment period (Figure 1), then every 12
weeks after discontinuation of study drug in patients who achieve
Table 1 Main Inclusion and Exclusion Criteria
Key Inclusion Criteria
Documented histologic or cytologic evidence of NSCLC (Stage IIIB/IV disease)
or recurrent/progressive disease following multimodal therapy (radiation
therapy, surgical resection, or deﬁnitive chemoradiation therapy for locally
advanced disease)
Received at least 2 prior systemic regimens for NSCLC
Disease progression or recurrence after both a platinum-based regimen and at
least 1 additional systemic regimen for NSCLC
World Health Organization performance status of 0 or 1
Estimated life expectancy of >12 weeks
Consent to provide tumor samples for assessment of PD-L1 membrane
staining on recently acquired tumor tissue (preferred) or an archival (3 years
old) tumor biopsy
Provision of archived tumor tissue (in addition to the samples used to
determine PD-L1 status) in a quantity sufﬁcient for analysis
At least 1 not previously irradiated lesion that can be accurately measured at
baseline according to RECIST v1.1
Key Exclusion Criteria
Mixed small-cell and nonesmall-cell histology
Known EGFR TK activating mutations or ALK rearrangements (patients with
EGFR TK inactivating mutations [eg, exon 20] are eligible)
Concurrent chemotherapy, biological, or hormonal therapy or treatment with an
investigational product for cancer
Prior exposure to any anti-CTLA-4 (Sub-study B only), anti-PD-1 or anti-PD-L1
antibodies
Any unresolved toxicity (CTCAE>Grade 2) from previous anticancer therapy
Any prior Grade 3 irAE while receiving any previous anti-cancer therapy
Brain metastases or spinal cord compression, unless asymptomatic, treated
and stable (not requiring steroid or anti-convulsant treatment for 1 month
prior to study entry)
Any major surgical procedure (as deﬁned by the study investigator) within 28
days of the ﬁrst dose of study medication
Current or prior use of immunosuppressive medication within 28 days of the
ﬁrst dose of study medication (except intranasal and inhaled corticosteroids or
systemic corticosteroids at doses 10 mg/day or prednisone or an equivalent
corticosteroid)
Evidence of severe or uncontrolled systemic disease, including active bleeding
diatheses or active infections including hepatitis B, C, and HIV
Active or prior documented autoimmune or inﬂammatory disorders
History of or active primary immunodeﬁciency
Abbreviations: ALK ¼ anaplastic lymphoma kinase; CTCAE ¼ Common Terminology Criteria for
Adverse Events; EGFR ¼ epidermal growth factor receptor; irAE ¼ immune-related adverse
event; NSCLC ¼ nonesmall-cell lung cancer; PD-1 ¼ programmed cell death-1; PD-L1 ¼
programmed cell death ligand-1; RECIST ¼ Response Evaluation Criteria In Solid Tumors; TK ¼
tyrosine kinase.
David Planchard et aldisease control after completion of the treatment period
(Figure 1) until conﬁrmed objective disease progression (conﬁr-
matory scan required following initial demonstration of pro-
gressive disease).
Conclusion
Anti-PD-1 and anti-PD-L1 monotherapies have shown clinical
activity in advanced NSCLC, but responses in patients with PD-
L1 tumors are often limited. Encouraging phase I/II data have
shown that combining the anti-PD-L1 antibody durvalumab and
the anti-CTLA-4 antibody tremelimumab may provide beneﬁt to
patients with PD-L1 tumors. The ARCTIC phase III study isinvestigating the safety and clinical activity of the durvalumab and
tremelimumab combination, which offers the potential to provide
clinical activity in patients with advanced NSCLC regardless of PD-
L1 status. Recruitment started in January 2015 and is currently
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Supplemental Table 1 List of Potential Factors for Assess-
ment of Exploratory Biomarkers
Factor
Tumor biomarkers
Box P3
CD3
CD4
CD8
CD45RO
Cleaved caspase 3
CTLA-4
Forkhead
Granzyme B
Ki67
Messenger RNA
Micro RNA
OX40
PD-1
PD-L1
Plasma and/or serum biomarkers
Antibodies against tumor/self
IL-2
IL-6
IL-10
IL-8
IL-12
Interferon-gamma
Messenger RNA
MicroRNA
Transforming growth factor-beta
Tumor necrosis factor-alpha
Viral antigens
Abbreviations: CD ¼ Cluster differentiation; CTLA-4 ¼ cytotoxic T lymphocyte-associated
antigen 4; IL ¼ interleukin; PD-1 ¼ programmed cell death-1; PD-L1 ¼ programmed cell
death ligand-1.
Supplemental Figure 1 Mechanism of Action. A, Durvalumab. B, Tremelimumab
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